BRD4-interacting chromatin-remodeling complex-associated protein (BICRA)

BRD4-interacting chromatin-remodeling complex-associated protein (BICRA) is a core component of the SWI/SNF chromatin remodeling subcomplex GBAF, which uses ATP-dependent mechanisms to alter chromatin structure by changing DNA-histone contacts within a nucleosome[1][4][6]. This remodeling capability directly influences gene expression, including BRD4-mediated gene transcription. In humans, genetic alterations in the BICRA gene have been associated with syndromic neurodevelopmental disorders, particularly those characterized by developmental delay, intellectual disability, autism spectrum disorder, and distinctive dysmorphic features[1]. The protein is also referred to as GLTSCR1, reflecting its identification as a candidate tumor suppressor gene within a glioma locus, although its cancer roles require further clarification. There are currently no known drugs that directly target BICRA, nor specified mechanisms of action, clinical biomarkers for therapy, or documented therapy safety concerns from the available literature[1][2][4].

Other names

CSS12GLTSCR1SMARCK1Glioma tumor suppressor candidate region gene 1 proteinBRD4 interacting chromatin remodeling complex associated protein